Rocket One (RKTO) Share-based Compensation (2017 - 2026)
Rocket One's (RKTO) quarterly Share-based Compensation came in at $2.3 million in Q2 2026, up 83.31% year-over-year from $1.3 million in Q2 2025, and up 83.31% quarter-over-quarter from $1.3 million in Q1 2026.
Analysis
Rocket One (RKTO) Share-based Compensation (2017 - 2026) Analysis & Trends
Rocket One has disclosed Share-based Compensation across 10 years of filings, most recently posting $2.3 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 83.31% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $2.3 million (up 83.31% YoY), while the FY2025 annual figure was $1.5 million, up 39.5% from the prior year.
- Share-based Compensation came in at $2.3 million for Q2 2026 at Rocket One, up from $1.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.3 million in Q2 2026 to a low of $541.0 in Q4 2024.
- Average Share-based Compensation over 5 years is $605940.8, with a median of $383851.5 recorded in 2022.
- Year-over-year, Share-based Compensation plunged 98.82% in 2022 and soared 20426.8% in 2025.
- Over 5 years, Share-based Compensation stood at $15468.0 in 2022, then tumbled by 62.6% to $5785.0 in 2023, then plunged by 90.65% to $541.0 in 2024, then soared by 20426.8% to $111050.0 in 2025, then jumped by 1980.47% to $2.3 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $2.3 million in Q2 2026, $1.3 million in Q1 2026, and $111050.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Rocket One | 13.86 Mn | 5.97 Mn | - | 2.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.31 Mn |
| Mar 31, 2026 | 1.26 Mn |
| Dec 31, 2025 | 111,050.00 |
| Sep 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 541.00 |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 617,362.00 |
| Mar 31, 2024 | 617,362.00 |
| Dec 31, 2023 | 5,785.00 |
| Sep 30, 2023 | 190,265.00 |
| Jun 30, 2023 | 104,651.00 |
| Mar 31, 2023 | 104,651.00 |
| Dec 31, 2022 | 15,468.00 |
| Sep 30, 2022 | 104,651.00 |
| Jun 30, 2022 | 15,538.00 |
| Mar 31, 2022 | 577,438.00 |
| Dec 31, 2021 | 125,991.00 |
| Sep 30, 2021 | 1.32 Mn |